Pfizer spin-out RaQualia heads towards delayed Japanese IPO
This article was originally published in Scrip
RaQualia Pharma's plans for an IPO in Japan are moving ahead after being postponed following the devastating 11 March earthquake and tsunami, with its shares due to start trading on the Osaka Stock Exchange's Jasdaq market on 20 July.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.